6-1 Month Momentum % is the total return of the stock from 6-month ago to 1-month ago. As of today (2022-08-13), Melinta Therapeutics's 6-1 Month Momentum % is -98.13%.
The industry rank for Melinta Therapeutics's 6-1 Month Momentum % or its related term are showing as below:
MLNTQ's 6-1 Month Momentum % is not ranked
in the Biotechnology industry.
Industry Median: -23.10
vs MLNTQ: -98.13
Competitive Comparison
For the Biotechnology subindustry, Melinta Therapeutics's 6-1 Month Momentum %, along with its competitors' market caps and 6-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Melinta Therapeutics 6-1 Month Momentum % Distribution
For the Biotechnology industry and Healthcare sector, Melinta Therapeutics's 6-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where Melinta Therapeutics's 6-1 Month Momentum % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 6-1 Month Momentum % measures the total return to a stock over the past six months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
Melinta Therapeutics 6-1 Month Momentum % Related Terms
Thank you for viewing the detailed overview of Melinta Therapeutics's 6-1 Month Momentum % provided by GuruFocus.com. Please click on the following links to see related term pages.
Melinta Therapeutics Inc is a clinical-stage biotechnology company that develops differentiated antibiotics for acute care and community settings. The company's goal is to develop treatments for bacterial infectious diseases, particularly respiratory tract infections and staphylococcal infections. The company is particularly focused on treating community-acquired bacterial pneumonia, as well as gonorrhea and other indications.
My Portfolios
Create New Portfolio
Portfolio Contest
My Gurus
Personalize
Premium Gurus 
0(0%) 9:40AM EDT
Email Alerts
Stock PDF
RSS
Website
Filings
Download
Manual of Stocks™ Web APP
OTCPK:MLNTQ has been successfully added to your 
